5 ESSENTIAL ELEMENTS FOR ABBV-744 DRUG DEVELOPMENT PROGRESS AND TIMELINE

In Section A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. More members is going to be enrolled on the identified monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will likely be specified as "incorporate-on" therapy. In Segmen